Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 18/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 13/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 9/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832990 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL192973 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL10017369 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL192857 | 0.96 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL10017372 | 0.96 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL14515933 | 0.96 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL10017366 | 0.95 | LPAR3 (0.90) | LPAR3LPAR2LPAR1 | |
| SCHEMBL31060667 | 0.89 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL193156 | 0.89 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL | |
| SCHEMBL14515931 | 0.89 | LPAR3 (1.00) | LPAR3LPAR2LPAR1ENPP2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2767541-A1 | LPA receptor agonists and antagonists | Rxbio, Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2262371-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | RXBIO INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | LPAR1, LPAR2, LPAR4 | LPAR3 4/4885LPAR2 2/4885LPAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.